# Junta clínica — PT-pseudo_2b3ef1d3a505 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_2b3ef1d3a505",
  "pid": "PT-pseudo_2b3ef1d3a505",
  "task": 1,
  "psa": 4.2,
  "age": 67,
  "months": 2,
  "pirads": "5",
  "psad": 0.06,
  "psav": 0.66,
  "psap": 3.7,
  "vol": 69.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.81166416,
  "medhx": "COPD",
  "meds": "tiotropium, salbutamol PRN",
  "notes": "PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.",
  "pmhx": [
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "66 kg",
    "height": "185 cm",
    "bmi": "19.3",
    "bp": "113/72 mmHg",
    "hr": "74 bpm",
    "smoking": "Ex-smoker (30 pack-yr, quit 2015)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "23 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review."
    },
    {
      "s": "History",
      "t": "A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent."
    }
  ],
  "occupation": "mechanical engineer",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Pulmonary function test — known COPD follow-up",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "31 units / week (heavy)",
  "exercise": "Light weight-training at home, 2x/week",
  "ipss": "IPSS score: 9/35 (moderate LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2b3ef1d3a505
Task: 1

Encounter: Urology - outpatient on 23 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.06 ng/mL²
  - PSA velocity: 0.66 ng/mL/yr
  - Prior PSA: 3.7 ng/mL
  - Prostate volume: 69.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81166416 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.

Vitals: weight 66 kg, height 185 cm, BMI 19.3, BP 113/72 mmHg, HR 74 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2015).

Chief complaint: Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review.

History: A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management.

Physical examination: DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 31 units / week (heavy); exercise Light weight-training at home, 2x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.52
  uncertainty  +/- 0.13 epistemic (95% band 0.26-0.79); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.36: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."
  2. distance 1.61: PI-RADS 5, PSA 8.6, PSAD 0.202, age 68, DRE Nodus -> BIOPSY (clear). He wrote: "Patient reasonable to discuss curative treatment with (age 68, no very dramatic comorbidity, unfavorable intermediate risk disease). Considering he chose not curative tr…"
  3. distance 1.68: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"

PRECEDENT: DEFER (weighted vote 0.32 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings, which are not fully detailed here. The precedent cited by Expert 5 suggests that the decision hinges on whether the P5 lesion has grown in size, which is a specific clinical question not resolved by the panel variables alone.

WHAT WE STILL NEED
The panel already contains: age (67), PSA (4.2 ng/mL), PI-RADS (5), PSA density (0.06 ng/mL²), prostate volume (69.0 mL), DRE finding (Nodus), prior-biopsy status (Positive), and csPCa probability (0.81166416).

The prior biopsy status is Positive, which is a known fact. The guideline requires information on the MRI findings to determine if a repeat biopsy is warranted.

The documented grade of the prior biopsy and the number and dates of biopsy sessions in the notes are needed to assess the histological progression.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on determining the histological progression of the prior biopsy, which is the key missing piece according to the EAU guidelines and the expert consensus.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the mpMRI, and is it compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy grade (Gleason/ISUP), number/dates of biopsies, and surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full laboratory results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI of the Prostate | Institution: Ziekenhuis Gelderse Vallei, Ede | Date: 15 January 2025
What is the lesion size and zone of the mpMRI, and is it compared against an earlier study?
The focal hypointense abnormality measures roughly 18 x 15 x 12 mm situated at the mid-gland level of the right peripheral zone. It is compared against an earlier study.

psa_trend
What is the trend of the serial PSA values (rising, flat, or falling)?
The trend of the serial PSA values is rising, with values recorded as 0.8 ng/mL in Jun 2023, 2.2 ng/mL in Dec 2023, 0.7 ng/mL in Jul 2024, and 4.2 ng/mL in Jan 2025.

previous_notes
What is the management context, including the prior biopsy grade (Gleason/ISUP), number/dates of biopsies, and surveillance protocol status?
The management context includes a prior positive biopsy yielding ISUP Grade Group 1 results. There is no explicit mention of the number or dates of prior biopsy sessions or a specific surveillance protocol status in the retrieved notes.

laboratory_results
What are the full laboratory results, including free-PSA fraction, renal function, and haemoglobin?
PSA is 4.2 ng/mL on 09 Dec 2024, Free PSA is 0.88 ng/mL on 09 Dec 2024, %Free PSA is 21% on 09 Dec 2024, Haemoglobin is 16.0 g/dL on 09 Dec 2024, Creatinine is 82 umol/L on 09 Dec 2024, and eGFR is >60 mL/min/1.73m2 on 09 Dec 2024.

WHAT I DID NOT OPEN
family-history anamnesis because the information was not explicitly requested by the moderator and is not critical for the immediate decision based on the other opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion in the right mid-peripheral zone from the radiology_report.
Rising PSA trend from the psa_trend.
Prior positive biopsy status noted in the structured panel.

AGAINST sampling this patient now
No documented prior biopsy grade (Gleason/ISUP) in the previous_notes.
No explicit surveillance protocol status in the previous_notes.

WHERE THIS LEANS
The findings point towards a need for further histological assessment due to the high-risk MRI finding and rising PSA, but the critical information regarding the prior biopsy grade and surveillance status remains missing.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.20 ng/mL over 4 points spanning 19 months; velocity +1.58 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 6.5 ng/mL, conformal 95% band 1.9-22.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.59
  uncertainty  +/- 0.10 epistemic (95% band 0.40-0.79), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.52  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.59  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.32  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.52 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—do not fully answer the moderator's questions. Specifically, the previous_notes do not document the prior biopsy grade (Gleason/ISUP) or the number/dates of prior biopsy sessions or surveillance protocol status.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a BIOPSY recommendation based on a weighted vote (p=0.52), despite the lack of a documented prior grade in the opened documents. The retrieved evidence supports the need for further assessment due to the PI-RADS 5 lesion and rising PSA trend, aligning with the expert consensus leaning towards biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy? This question remains unanswered as the previous_notes did not contain this information.
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? This question remains unanswered as the previous_notes did not contain this information.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS 5 lesion in the right mid-peripheral zone from the radiology_report, which indicates high-risk MRI findings, and the rising PSA trend from the psa_trend, which indicates disease progression. These factors strongly support the need for further histological assessment.

MY SUGGESTION TO THE CHAIR
Given that the critical information regarding the prior biopsy grade and surveillance status is missing from the retrieved documents, the decision cannot be definitively made according to the EAU guideline's requirement for histological progression assessment. Therefore, the case is not ready for a final decision.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

A biopsy is recommended because the high-risk PI-RADS 5 lesion in the right mid-peripheral zone, combined with a rising PSA trend, indicates disease progression requiring histological assessment. This decision is supported by the combination of the high-risk imaging finding and the rising PSA trajectory, which together necessitate further histological evaluation.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
